 BALTIMORE--BUSINESS WIRE--MyMD Pharmaceuticals, Inc. Nasdaq: MYMD MyMD or the Company, a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office USPTO has issued U.S. Patent No. 11,085,047 titled Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders. The patent protects the Companys drug candidate Supe 